Biotechnology News and Research

RSS

Pro-Vas male contraceptive procedure available to physicians across the U.S.

Pro-Vas is the first male contraceptive procedure, other than condoms or vasectomy, to provide effective affordable birth control for men and it is available to physicians across the United States immediately.

1 Apr 2010

Teva Pharmaceutical Industries settles generic eloxatin patent infringement litigation

Teva Pharmaceutical Industries Ltd. announced today that patent infringement litigation pertaining to Teva's generic version of sanofi-aventis and Debiopharm's Eloxatin (oxaliplatin injection) has been dismissed by the United States District Court for the District of New Jersey pursuant to a settlement between the parties.

1 Apr 2010

Clearstone Central announces testing capability expansion at Toronto laboratory

Clearstone Central Laboratories, a leading global provider of clinical laboratory and centralized cardiac services for clinical trials, today announced the expansion of testing capabilities at its Toronto laboratory. Additional safety as well as esoteric testing capacity and capabilities will be added to the existing operations.

1 Apr 2010

ADDF grants Signum Biosciences $270,000 for evaluating PP2A-modulatory compounds as AD therapeutics

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it is providing a grant of $270,000 to Signum Biosciences, Inc. (Princeton, NJ) to evaluate small-molecule, orally delivered Protein Phosphatase 2a (PP2A)-modulatory compounds as disease-modifying therapeutics for Alzheimer's disease.

1 Apr 2010

LAB Research reports 9% decrease in revenues for 2009

LAB Research Inc., a global Canadian-based non-clinical contract research organization, today announced its fourth quarter and 2009 year-end financial results.

1 Apr 2010

States face health care budget cuts, seek health-related legislation

Parents, caregivers and advocates joined hospital executives and legislators Tuesday to complain about the potential impact of [Louisiana] Gov. Bobby Jindal's proposed budget cuts and privatization initiatives on Louisiana's most vulnerable residents.

1 Apr 2010

IGEN Networks signs MOU with Bio Business Development

IGEN Networks Corp. is pleased to announce that it has signed a memorandum of understanding with Bio Business Development Corp. International, Inc. to negotiate the acquisition of the exclusive global distribution rights to the patented lateral-flow diagnostic testing platform technology for rapid detection of the infectious prion protein diseases.

1 Apr 2010

Positive results from Phase 2 clinical trial of OMS103HP

Omeros Corporation today announced that a Phase 2 clinical trial of OMS103HP, its PharmacoSurgery™ product candidate for arthroscopy, demonstrated that patients treated with OMS103HP during arthroscopic knee meniscectomy surgery achieved statistically significant clinical benefits.

1 Apr 2010

New medicines to fight diseases of particular concern to African Americans

A recent article in The Triangle Tribune pointed to good news for members of the black community, highlighting new medicines in development to fight diseases of particular concern to African Americans.

1 Apr 2010

VIVUS terminates Luramist development, commercialization agreement with FemPharm

VIVUS, Inc. today announced that it has terminated the Development and Commercialization Agreement with FemPharm Pty Ltd. (a wholly owned subsidiary of Acrux Limited) for Luramist™, a metered dose transdermal application of testosterone for women.

1 Apr 2010

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc. announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity. The NDA is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical program, which included over 4,500 patients.

1 Apr 2010

GeneLink's net sales for fourth-quarter of 2009 increased by 9.7%

GeneLink, Inc., a leading consumer genomics biotech company, today reported financial results for the fiscal year ended December 31, 2009.

1 Apr 2010

Court rules against gene patents

The New York Times: A judicial ruling that "threw out parts of two gene patents and called into question thousands more" has biotechnology executives hastening "to reassure their investors that the ruling would not necessarily undermine their businesses, at least in the short run. But the executives themselves were struggling on Tuesday to figure out what the long-term impact would be."

1 Apr 2010

Positive results from Ardea Biosciences' Phase 2b study of RDEA594 for hyperuricemia and gout

Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd RDEA594, 600 mg qd RDEA594 or matching placebo.

1 Apr 2010

BioCision, Biohit announce co-promotion program

BioCision LLC today announced that it has agreed to a co-promotion program with Biohit Inc.. Biohit's ErgoTube microcentrifuge tubes will now be branded and sold by both Biohit Inc. and BioCision. In addition, Biohit Inc. will cross-promote BioCision's highly thermo-conductive CoolRack microfuge tube racks for use in combination with ErgoTubes.

31 Mar 2010

RXi Pharmaceuticals reports net loss of 28% for 2009

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today reported financial results for the fourth quarter and year ended December 31, 2009.

31 Mar 2010

BBSRC, NSF to hold intensive week long facilitated workshop to enhance photosynthesis

Leading bioscience funding bodies in the UK and USA announce plans to promote scientific proposals in the potentially transformational area of enhanced photosynthesis.

31 Mar 2010

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

ArQule, Inc. today announced that ARQ 197, when used in combination with erlotinib, demonstrated a 66% improvement in median Progression-Free Survival in patients with advanced, refractory non-small cell lung cancer.

31 Mar 2010

Astellas Pharma forms agreement to review certain confidential information of OSI Pharmaceuticals

OSI Pharmaceuticals, Inc. today announced that it had entered into an agreement with Astellas Pharma Inc., under which Astellas will be able to review certain confidential information related to OSI.

31 Mar 2010

2010 BIO International Convention to discuss issues that impact drug discovery and development

The 2010 BIO International Convention will feature a robust health and medical program highlighting the latest scientific breakthroughs and policy and business development issues that impact drug discovery and development. Hosted by the Biotechnology Industry Organization, the Convention will be held May 3-6, 2010 in Chicago, Ill. at McCormick Place.

31 Mar 2010

Biotechnology News and Research

Pro-Vas male contraceptive procedure available to physicians across the U.S.

Teva Pharmaceutical Industries settles generic eloxatin patent infringement litigation

Clearstone Central announces testing capability expansion at Toronto laboratory

ADDF grants Signum Biosciences $270,000 for evaluating PP2A-modulatory compounds as AD therapeutics

LAB Research reports 9% decrease in revenues for 2009

States face health care budget cuts, seek health-related legislation

IGEN Networks signs MOU with Bio Business Development

Positive results from Phase 2 clinical trial of OMS103HP

New medicines to fight diseases of particular concern to African Americans

VIVUS terminates Luramist development, commercialization agreement with FemPharm

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

GeneLink's net sales for fourth-quarter of 2009 increased by 9.7%

Court rules against gene patents

Positive results from Ardea Biosciences' Phase 2b study of RDEA594 for hyperuricemia and gout

BioCision, Biohit announce co-promotion program

RXi Pharmaceuticals reports net loss of 28% for 2009

BBSRC, NSF to hold intensive week long facilitated workshop to enhance photosynthesis

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

Astellas Pharma forms agreement to review certain confidential information of OSI Pharmaceuticals

2010 BIO International Convention to discuss issues that impact drug discovery and development

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News